Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum

Thorax

Volumn 68, Issue 7, 2013, Pages 652-657

  Baxter, Caroline G ^a,b   Rautemaa, Riina ^a,b   Jones, Andrew M ^a   Kevin Webb, A ^a   Bull, Matthew ^c   Mahenthiralingam, Eshwar ^c   Denning, David W ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIGEN; AZTREONAM; CEFTAZIDIME; FUNGAL DNA; GALACTOMANNAN ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASPERGILLUS; ASPERGILLUS FUMIGATUS; BACTERIAL COLONIZATION; CLINICAL ARTICLE; COHORT ANALYSIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNGAL DETECTION; FUNGUS CULTURE; GENETIC PROCEDURES; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG FUNCTION; MALE; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY VIRUS; RIBOSOMAL INTERGENIC SPACER ANALYSIS; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; SPUTUM CULTURE; TREATMENT DURATION;

ASPERGILLUS LUNG DISEASE; CYSTIC FIBROSIS; RESPIRATORY INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, FUNGAL; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CYSTIC FIBROSIS; DNA, FUNGAL; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES; PSEUDOMONAS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; SPUTUM; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84879422150     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202412     Document Type: Article

References (30)

1. Nagano Y, Elborn JS, Millar BC, et al. Comparison of techniques to examine the diversity of fungi in adult patients with cystic fibrosis. Med Mycol 2010;48:166-76 e1.
2. Bittar F, Rolain JM. Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients. Clin Microbiol Infect 2010;16:809-20.
3. Valenza G, Tappe D, Turnwald D, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008;7:123-7. (Pubitemid 351372763)
4. Singh PK, Schaefer AL, Parsek MR, et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407:762-4.
5. Muller FM, Seidler M, Beauvais A. Aspergillus fumigatus biofilms in the clinical setting. Med Mycol 2011;49(Suppl 1):S96-S100.
6. Loussert C, Schmitt C, Prevost MC, et al. In vivo biofilm composition of Aspergillus fumigatus. Cell Microbiol 2009;12:405-10.
7. Bakare N, Rickerts V, Bargon J, et al. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 2003;46:19-23. (Pubitemid 36278895)
8. Baxter CG, Jones AM, Webb K, et al. Homogenisation of cystic fibrosis sputum by sonication-an essential step for Aspergillus PCR. J Microbiol Methods 2011;85:75-81.
9. Kerr JR. Suppression of fungal growth exhibited by Pseudomonas aeruginosa. J Clin Microbiol 1994;32:525-7. (Pubitemid 24033926)
10. Mowat E, Rajendran R, Williams C, et al. Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol Lett 2010;313:96-102.
11. Tunney MM, Klem ER, Fodor AA, et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011;66:579-84.
12. Jubin V, Ranque S, Stremler Le Bel N, et al. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010;45:764-71.
13. Bargon J, Dauletbaev N, Kohler B, et al. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med 1999;93:835-8.
14. Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease. Thorax 2012;67:456-63.
15. Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology 2007;153:917-23. (Pubitemid 46605791)
16. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38. (Pubitemid 41079078)
17. Health Protection Agency. UK Standards for Microbiology Investigations. Investigation of bronchoalveolar lavage, sputum and associated specimens; BSOP 57, 2008. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317132860548 (accessed 24 Nov 2012).
18. Borneman J, Triplett EW. Molecular microbial diversity in soils from eastern Amazonia: evidence for unusual microorganisms and microbial population shifts associated with deforestation. Appl Environ Microbiol 1997;63:2647-53. (Pubitemid 27292855)
19. White J, Gilbert J, Hill G, et al. Culture-independent analysis of bacterial fuel contamination provides insight into the level of concordance with the standard industry practice of aerobic cultivation. Appl Environ Microbiol 2011;77:4527-38.
20. White PL, Perry MD, Moody A, et al. Evaluation of analytical and preliminary clinical performance of Myconostica MycAssay Aspergillus when testing serum specimens for diagnosis of invasive Aspergillosis. J Clin Microbiol 2011;49:2169-74.
21. Myconostica. MycXtra DNA extraction-effective extraction of fungal DNA from clinical respiratory samples. http://myconostica.co.uk/mycxtra (accessed 24 Nov 2012).
22. Regelmann WE, Elliott GR, Warwick WJ, et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-21. (Pubitemid 20157719)
23. Kerr JR, Taylor GW, Rutman A, et al. Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathol 1999;52:385-7. (Pubitemid 29200034)
24. Kobayashi H. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections. Treat Respir Med 2005;4:241-53. (Pubitemid 41252835)
25. Seidler MJ, Salvenmoser S, Muller FM. Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob Agents Chemother 2008;52:4130-6.
26. Lutz L, Pereira DC, Paiva RM, et al. Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. BMC Microbiol 2012;12:196.
27. Yadav V, Gupta J, Mandhan R, et al. Investigations on anti-Aspergillus properties of bacterial products. Lett Appl Microbiol 2005;41:309-14. (Pubitemid 41392470)
28. Hope WW, Petraitis V, Petraitiene R, et al. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) beta-d-glucan and consequences of delayed antifungal therapy. Antimicrob Agents Chemother 2010;54:4879-86.
29. Boonsarngsuk V, Niyompattama A, Teosirimongkol C, et al. False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. Scand J Infect Dis 2010;42:461-8.
30. Baxter CG, Moore CB, Jones AM, et al. IgE mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. Chest. Published Online First: 8 November 2012. doi:10.1378/chest.12-1363.